A feasibility and Randomized phase 2/3 study of the VEFGR2/MET inhibitor Cabozanitinib in combination with cytotoxic chemotherapy for newly diagnosed osteosarcoma

Sponsor:

COG

Sponsor Study ID:

AOST2032

CTO #:

103883

NCT Number:

NCT05691478

Phase:

II/III

Protocol Type:

Treatment

Age Group:

Children

Disease Sites:

Bones and Joints

Study Objectives:

Primary Aims 1.1.1 1.1.2 1.1.3 To determine the feasibility of adding cabozantinib to standard MAP (high dose methotrexate, doxorubicin, and cisplatin) chemotherapy in patients with newly diagnosed metastatic osteosarcoma with a resectable primary tumor. To determine whether MAP chemotherapy plus cabozantinib results in more favorable event-free survival (EFS) than MAP chemotherapy alone in patients with localized, resectable osteosarcoma. To determine whether MAP chemotherapy plus cabozantinib results in more favorable event-free survival (EFS) than MAP chemotherapy alone in patients with metastatic, pelvic and unresectable osteosarcoma.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)

---

Request more information